21213 ⎘
Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen Lipids, e.g. in lipopeptides
Single Domain Anti-CD169 Antibodies
#2DEVELOPMENT OF MULTI-ANTIGEN MRNA VACCINE AGAINST FELINE FIPV
#3LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES
#4METHODS FOR ASSEMBLING PROTEIN-CONJUGATED NANOCARRIER VACCINES
#5Ultrapurified Phospholipoproteomic Composition for High-Purity Biomolecular Research and Precision Therapeutics
#6BETACORONAVIRUS mRNA VACCINES
#7Tumor-Associated Antigen Based Cancer Vaccine
#8BETACORONAVIRUS mRNA VACCINES
#9CORONAVIRUS VACCINE
#10NOVEL COMPOSITIONS COMPRISING TERPENOID AND MACROMOLECULE, AND USES THEREOF
#11CATIONIC LIPID BASED COMPOSITION, FORMULATION AND USE FOR NUCLEIC ACID VACCINE DELIVERY AND PREPARATION THEREOF
#12POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF
#13VACCINE ANTIGENS AND USE THEREOF
#14AMINO LIPID COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF
#15Methods and Compositions for Treating Infections
#16HTLV-1 NUCLEIC ACID LIPID PARTICLE VACCINE
#17FAP2-DERIVED ANTIBODIES AND VACCINES AGAINST FUSOBACTERIUM
#18ALLERGY VACCINES BASED ON CONSENSUS ALLERGENS
#19HERPES ZOSTER mRNA VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF
#20IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE
#21mRNA-based HIV Vaccine For Acute and Latent Infections
#22RESPIRATORY SYNCYTIAL VIRUS RNA VACCINATION
#23METHOD FOR SUSTAINED DELIVERY OF MRNA VACCINES
#24ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS TO TREAT METABOLIC DISORDERS
#25NUCLEIC ACID BASED VACCINE ENCODING AN ESCHERICHIA COLI FIMH ANTIGENIC POLYPEPTIDE
#26LIPID NANOCARRIER VACCINE
#27IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA
#28Compositions of Phosphorylated Tau Peptides and Uses Thereof
#29EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY
#30Method of Safe Administration of Phosphorylated TAU Peptide Vaccine
#31NUCLEIC ACIDS ENCODING A CONSTITUTIVELY-ACTIVE CYCLIC GMP-AMP SYNTHASE AND IMMUNOGENIC DELIVERY VEHICLES FOR SAME
#32MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS
#33HUMAN CYTOMEGALOVIRUS VACCINE
#34LIPID-BASED FORMULATIONS FOR ADMINISTRATION OF RNA
#35CORONAVIRUS VACCINE
#36CLOSTRIDIUM DIFFICILE VACCINE
#37COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF RABIES VIRUS INFECTION
#38RNA ADJUVANTS, METHODS AND USES THEREOF
#39CORONAVIRUS VACCINE
#40BETACORONA VIRUS mRNA VACCINES
#41BETACORONAVIRUS mRNA VACCINES
#42IONIZABLE CATIONIC COMPOUNDS FOR MESSENGER RNA DELIVERY
#43VACCINE COMPOSITIONS
#44HIV RNA VACCINES
#45IMPROVED CIRCULAR RNA FOR EXPRESSING THERAPEUTIC PROTEINS
#46METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY
#47RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATION
#48COMPOSITIONS FOR USE IN TREATMENT OF ACNE
#49COMBINATION HMPV/RSV RNA VACCINES
#50Betacoronavirus RNA vaccines
#51HAEMOPHILUS INFLUENZAE SACCHARIDE-CARRIER CONJUGATE COMPOSITIONS AND USES THEREOF
#52COMBINATION HMPV/RSV RNA VACCINES
#53COMBINATION HMPV/RSV RNA VACCINES
#54IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES
#55RNA ADSORBED ONTO LIPID NANO-EMULSION PARTICLES AND ITS FORMULATIONS
#56POLY(ETHYLENE GLYCOL) HAVING C1 TO C3-ALKYLOXYMETHYL SIDE CHAINS, BIOCONJUGATES THEREOF, PROCESS FOR ITS PREPARATION AND ITS USE
#57CORONAVIRUS GLYCOSYLATION VARIANT VACCINES
#58MULTIPLE FUNCTIONALIZED noMV CONJUGATES
#59CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS
#60Coronavirus vaccine
#61TARGETING OF ANTIGEN-PRESENTING CELLS BY NANOPARTICLES CONTAINING POLYOXAZOLINE-LIPID CONJUGATES
#62Vaccine Therapy
#63"Good" buffer-based cationic lipids
#64RSV RNA molecules and compositions for vaccination
#65CANCER IMMUNOTHERAPY BY DELIVERY OF mRNA
#66HTLV-1 NUCLEIC ACID LIPID PARTICLE VACCINE
#67IMMUNOSTIMULATORY COMPOSITIONS
#68EPSTEIN-BARR VIRUS MRNA VACCINES
#69COMPOSITIONS AND METHODS FOR PREVENTING RSV AND PIV3 INFECTIONS
#70IMMUNOGENIC COMPOSITIONS
#71Composition and methods for MRNA vaccines against novel omicron coronavirus infections
#72RNA VACCINE AGAINST SARS-COV-2 VARIANTS
#73IMMUNOSTIMULATORY COMPOSITIONS
#74IONIZABLE LIPIDS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY
#75COMPOSITIONS AND METHODS FOR STABILIZATION OF LIPID NANOPARTICLE MRNA VACCINES
#76BIOCOMPATIBLE NANOCOMPOSITE HYDROGEL IMMUNOTHERAPY VACCINES AND METHODS OF USE THEREOF
#77BACTERIAL OUTER MEMBRANE VESICLES CARRYING CORONAVIRUS POLYPEPTIDES, METHOD OF PREPARATION, COMPOSITIONS AND USE THEREOF
#78EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY
#79AMBIENT TEMPERATURE LIPID PARTICLE STORAGE SYSTEMS AND METHODS
#80Influenza vaccines
#81Method of Safe Administration of Phosphorylated TAU Peptide Vaccine
#82Coronavirus vaccine
#83ANTIBODY-MEDIATED NEUTRALIZATION OF BETA-LACTAMASES
#84HEPATITIS C VIRUS MODIFIED E2 GLYCOPROTEIN AND USES THEREOF AS VACCINES
#85Coronavirus vaccine
#86Coronavirus vaccine
#87CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF
#88Heterologous Administration of Tau Vaccines
#89Ionizable lipids and compositions for nucleic acid delivery
#90EDIBLE PLANT EXOSOME-LIKE NANOVECTORS FOR VACCINATION
#91POLYNUCLEOTIDES COMPRISING AN ANTIGENIC PAYLOAD
#92RNA-LOADED NANOPARTICLES AND USE THEREOF FOR THE TREATMENT OF CANCER
#93METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY
#94CELL SURFACE ANCHORING ANTIGEN CONJUGATES TO TREAT CANCER
#95SEASONAL RNA INFLUENZA VIRUS VACCINES
#96TREATMENT INVOLVING IMMUNE EFFECTOR CELLS GENETICALLY MODIFIED TO EXPRESS ANTIGEN RECEPTORS
#97Coronavirus vaccine
#98IMMUNOGENIC COMPOSITION AGAINST INFLUENZA
#99Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
#100LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
#101saccharide-carrier conjugate compositions and uses thereof
#102METHODS AND COMPOSITIONS OF ASTROVIRUS REPLICONS
#103HIV RNA vaccines
#104Methods and compositions for treating infections
#105ONE-STEP ARTIFICIAL ANTIGEN PRESENTING CELL-BASED VACCINES
#106ANTI-ABETA VACCINE THERAPY
#107MACROCYCLIC LIPIDS
#108Covalently modified antigens for improved immune response and/or stability
#109Nucleic acid vaccines for coronavirus
#110Coronavirus vaccine
#111METHODS OF TREATING TUBERCULOSIS
#112MOMP telonanoparticles, and related compositions, methods and systems
#113Coronavirus vaccine
#114Therapeutics for autoimmune disease: synthetic antigens
#115Mutant fragments of OspA and methods and uses relating thereto
#116METHODS AND COMPOSITIONS COMPRISING CATIONIC LIPIDS FOR IMMUNOTHERAPY BY DIRECT TUMOR INJECTION
#117ALPHAVIRUS NEOANTIGEN VECTORS AND INTERFERON INHIBITORS
#118Human cytomegalovirus vaccine
#119Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders
#120Antigen Delivery Vectors and Constructs
#121Human cytomegalovirus vaccine
#122LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES
#123Multi-functionalized nOMV conjugates
#124Influenza vaccines
#125Compositions of Phosphorylated Tau Peptides and Uses Thereof
#126METHODS FOR IDENTIFYING CHIMERIC ANTIGEN RECEPTOR-TARGETING LIGANDS AND USES THEREOF
#127EDIBLE PLANT EXOSOME-LIKE NANOVECTORS FOR VACCINATION
#128HEPATITIS B VACCINE
#129Cationic lipids comprising a steroidal moiety
#130Immunostimulatory compositions, particles, and uses related thereto
#131Antigen-surface-coupled liposome vaccine for non-human animals
#132Cyclic peptides for protection against respiratory syncytial virus
#133Methods and agents including STING agonist to treat tumor
#134Exosomes for immuno-oncology and anti-inflammatory therapy
#135Combination HMPV/RSV RNA vaccines
#136CLOSTRIDIUM PERFRINGENS SURFACE GLYCANS AND USES THEREOF
#137Compositions of phosphorylated tau peptides and uses thereof
#138Heterologous administration of tau vaccines
#139Human cytomegalovirus vaccine
#140AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION PROCESS
#141Betacoronavirus mRNA vaccine
#142Method of safe administration of phosphorylated tau peptide vaccine
#143Mutant fragments of OspA and methods and uses relating thereto
#144Betacoronavirus mRNA vaccine
#145Genetically attenuated nucleic acid vaccine
#146Tumor vaccine and uses thereof
#147MOMP telonanoparticles, and related compositions, methods and systems
#148Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
#149Human cytomegalovirus vaccine
#150PARTICULATE VACCINE FORMULATIONS
#151Amino acid and peptide conjugates and uses thereof
#152Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
#153NOVEL SYNTHETIC ANTICANCER, ANTIFUNGAL, AND ANTIBACTERIAL VACCINES
#154HPIV3 RNA vaccines
#155Synthetic lipopeptide vaccines and immunotherapeutics
#156Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
#157Toll-like receptor 2 agonists and vaccines and uses thereof
#158hMPV RNA vaccines
#159Exosomes for immuno-oncology and anti-inflammatory therapy
#160Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders
#161Oligonucleotide constructs and uses thereof
#162Adjuvanting meningococcal factor H binding protein
#163Compositions of phosphorylated tau peptides and uses thereof
#164Methods of treating cancer cells expressing tumor-associated integrins
#165LIPIDATED STREPTOCOCCUS PNEUMONIAE ANTIGEN COMPOSITIONS, METHODS OF PREPARATION AND USE
#166Mutant fragments of OspA and methods and uses relating thereto
#167Combination PIV3/hMPV RNA vaccines
#168Cell surface anchoring antigen conjugates to treat cancer
#169Chimeric OspA genes, proteins and methods of use thereof
#170Methods and compositions for liposomal formulation of antigens and uses thereof
#171PROLINE-RICH PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE
#172Influenza vaccines
#173METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY
#174Immunogenic compositions containing bacterial outer membrane vesicles
#175Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
#176Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
#177Immunostimulatory compositions, particles, and uses related thereto
#178Thermostable vaccines based on ether lipids and native viral envelope proteins
#179Amino acid and peptide conjugates and uses thereof
#180Toxoid preparation and uses thereof
#181Lipidated antigen compositions, methods of preparation and use
#182Adjuvanting meningococcal factor H binding protein
#183NOVEL SYNTHETIC ANTICANCER, ANTIFUNGAL, AND ANTIBACTERIAL VACCINES
#184Gas-filled microvesicles for use as vaccine
#185Antibodies With Simultaneous Subsite Specificities To Protein and Lipid Epitopes
#186MODULATION OF NKT CELL ACTIVITY WITH ANTIGEN-LOADED CD1d MOLECULES
#187Compositions comprising CH505 envelopes, and trimers
#188Lipid membrane structure for intracellular delivery of siRNA
#189Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines
#190ULTRAFILTRATION FOR PREPARING OUTER MEMBRANE VESICLES
#191SYNERGISTIC TUMOR TREATMENT WITH IL-2, A THERAPEUTIC ANTIBODY, AND A CANCER VACCINE
#192Methods and compositions for liposomal formulation of antigens and uses thereof
#193Mutant fragments of OspA and methods and uses relating thereto
#194Mutant fragments of OspA and methods and uses relating thereto
#195Amino acid and peptide conjugates and conjugation process
#196Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
#197Xenoantigen-displaying anti-cancer vaccines and method of making
#198Influenza antigen delivery vectors and constructs
#199Lipid vesicle compositions and methods of use
#200TOXOID PREPARATION AND USES THEREOF
#201composition and methods thereof
#202Proline-rich peptides protective against
#203Anti-aP2 antibodies and antigen binding agents to treat metabolic disorders
#204Cationic lipid formulations for regressing established tumor
#205Chimeric OspA genes, proteins and methods of use thereof
#206Glycan conjugates and methods of use thereof
#207Nanodisk-associated immunogen super polyvalent vaccines
#208Immunity inducer for saccharide antigens
#209Neisseria meningitidis compositions and methods thereof
#210Nanoparticle Delivery of TLR Agonists and Antigens
#211Conjugate compounds
#212Hepatitis C virus liposome vaccine
#213Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
#214MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO
#215Pharmaceutical composition comprising a solid nanoparticle and at least an antigen for the treatment against an intracellular pathogenic agent
#216Flagellin fusion proteins
#217Immunogenic composition and uses thereof
#218Glycoengineered outer membrane vesicles and use thereof as vaccines
#219Antigen delivery vectors and constructs
#220Glycopeptide and uses thereof
#221Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making
#222Compositions and methods for immune tolerance induction
#223Compositions and methods for treating influenza
#224Monophosphorylated lipid A derivatives
#225COMPOSITION FOR TARGETING DENDRITIC CELLS
#226Methods and compositions for liposomal formulation of antigens and uses thereof
#227Influenza antigen delivery vectors and constructs
#228Glycopeptide and uses thereof
#229Vaccine engineering
#230compositions and methods thereof
#231Methods of making hemagglutinin proteins
#232Synthetic immunogen useful for generating long lasting immunity and protection against pathogens
#233Methods of treatment with compositions that include hemagglutinin
#234Formulations which stabilize and inhibit precipitation of immunogenic compositions
#235ACYL PSEUDOPEPTIDES WHICH CARRY A FUNCTIONALIZED AUXILIARY ARM
#236PURIFICATION OF BACTERIAL VESICLES
#237Antigen delivery vectors and constructs
#238PEPTIDE CONJUGATES FOR SUPPRESSING AN IMMUNE RESPONSE, METHODS OF MAKING AND USES THEREFOR
#239Vaccine for Modulating Between T1 and T2 Immune Responses
#240Vaccine for modulating between T1 and T2 immune responses
#241Method of inducing neutralizing antibodies to human immunodeficiency virus
#242Lipid vesicle compositions and methods of use
#243Adjuvanting meningococcal factor H binding protein
#244Lipidated polyepitope vaccines
#245ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN
#246IMMUNOGENIC COMPOSITION AND USES THEREOF
#247Lipids and compositions for the delivery of therapeutics
#248GLYCOPEPTIDE AND USES THEREOF
#249Antigen delivery vectors and constructs
#250Chimeric OspA genes, proteins, and methods of use thereof
#251Peptides presenting an epitope of a domain of factor H binding protein and methods of use
#252Splitting GP41
#253Chimeric OspA genes, proteins, and methods of use thereof
#254Immunogenic lipopeptides comprising T-helper and cytotoxic T-lymphocyte (CTL) epitopes
#255SYNTHETIC VACCINE COMPONENT
#256Composition for targeting dendritic cells
#257ADJUVANTING MATERIAL
#258Compositions and Methods for the Treatment and Prophylaxis of Multiple Strains and Subtypes of HIV-1
#259Dendritic cell vaccines
#260Multi-component L2 vaccine for prevention of human papilloma virus infection
#261NOVEL FORMULATIONS WHICH STABILIZE AND INHIBIT PRECIPITATION OF IMMUNOGENIC COMPOSITIONS
#262Novel Compositions and Adjuvants
#263Vaccine
#264METHODS OF TREATING AND PROTECTING AGAINST HUMAN IMMUNODEFICIENCY VIRUS
#265Compositions that Include Hemagglutinin, Methods of Making and Methods of Use Thereof
#266Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same
#267Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
#268REAGENTS FOR INDUCING AN IMMUNE RESPONSE
#269Increase of immune response and targeting by antigens and/or drug linkage
#270Compositions comprising nucleic acids encoding HIV-1 reverse transcriptase CTL epitopes
#271Lipidated tumor-associated antigens and immunotherapeutic compositions
#272Method of transfection and compositions therefor
#273Method for therapeutic use
#274MULTICOMPONENT VACCINE
#275SYNTHETIC, SELF ADJUVANTING VACCINES
#276Methods and compositions for liposomal formulation of antigens and uses thereof
#277Acyl pseudodipeptides which carry a functionalized auxiliary arm
#278Antigen delivery vectors and constructs
#279Antigen delivery vectors and constructs
#280IMMUNOGENIC MOLECULES
#281ANTI-HIV IMMUNOGENIC FORMULATION AND PROCESS FOR PREPARATION THEREOF
#282Immunogenic lipopeptides comprising T-helper and B-cell epitopes
#283Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates
#284Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus
#285REVERSE TARGETING LIPID VESICLE
#286VACCINE
#287Lipidating sequences and use thereof for producing lipidated proteins in
#288Virosome-like vesicles comprising gp41-derived antigens
#289Liposome-mediated ligation
#290Influenza antigen delivery vectors and constructs
#291Compositions of influenza viral proteins and methods of use thereof
#292Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site
#293Multivalent Immunogen
#294VACCINE
#295TRUNCATED LHRH FORMULATIONS
#296Method of making immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particles devoid of CD55 and CD59 in the viral membrane
#297Method of inducing an immune response in a host by administering immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particles devoid of CD55 and CD59 in the viral membrane
#298Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
#299THERAPEUTIC AGENT FOR ALLERGY CONTAINING LIPOSOME HAVING OLIGOSACCHARIDE ON ITS SURFACE
#300Cationic lipid-mediated enhancement of nucleic acid immunization of cats